- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00740935
Impact of Systematic Infants Vaccination Against Rotavirus on Gastroenteritis Hospitalization: a Prospective Study in Brest District, France. (IVANHOE)
Universal rotavirus vaccination program for infants born in Brest after February 2007, applied by the Centers for Maternal and Infant Health Protection, pediatricians and general practitioners.
Prospective surveillance of hospitalizations for gastroenteritis within the Pediatric Units of Brest University Hospital with systematic testing for Rotavirus.
Evaluation of the impact of the vaccination program on rotaviral gastroenteritis hospitalizations from 2007-2008 and 2008-2009, by comparison with epidemiological data from 2002-2007 in the absence of vaccination.
The principal judgement criterion is the number of pediatric hospitalizations for rotaviral GEA during the 2008-2009 epidemic in children A) under the age of 2 and B) residing in the suburbs of Brest.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Brest, France, 29200
- Clinical Investigation Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- infants aged 6 to 12 weeks
- born in Brest District, France
- born between Feb 01, 2007 and Nov 19, 2009
Exclusion Criteria:
- contraindication to rotavirus vaccine
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: 1
Cohort of vaccinated infants against rotavirus
|
Vaccination against rotavirus Three oral doses (2 mL) between 6 to 26 weeks of life with at least 4 weeks between each dose.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Hospitalization for gastroenteritis
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Emergency department consultation for gastroenteritis
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Arnaud GAGNEUR, Doctor, University Hospital, Brest
Publications and helpful links
General Publications
- Roue JM, Nowak E, Le Gal G, Lemaitre T, Oger E, Poulhazan E, Giroux JD, Garenne A, Gagneur A. Impact of rotavirus vaccine on premature infants. Clin Vaccine Immunol. 2014 Oct;21(10):1404-9. doi: 10.1128/CVI.00265-14. Epub 2014 Jul 30.
- Gagneur A, Nowak E, Lemaitre T, Segura JF, Delaperriere N, Abalea L, Poulhazan E, Jossens A, Auzanneau L, Tran A, Payan C, Jay N, de Parscau L, Oger E; IVANHOE investigators. Impact of rotavirus vaccination on hospitalizations for rotavirus diarrhea: the IVANHOE study. Vaccine. 2011 May 12;29(21):3753-9. doi: 10.1016/j.vaccine.2011.03.035. Epub 2011 Apr 13.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RB 06.117
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rotavirus Gastroenteritis
-
GlaxoSmithKlineCompletedRotavirus Gastroenteritis | Nosocomial Rotavirus Gastroenteritis
-
GlaxoSmithKlineCompletedInfections, Rotavirus | Rotavirus Gastroenteritis
-
Romark Laboratories L.C.CompletedRotavirus Infection | Viral Gastroenteritis Due to RotavirusEgypt
-
Sinovac Life Sciences Co., Ltd.CompletedRotavirus GastroenteritisChina
-
University Hospital for Infectious Diseases, CroatiaCompletedRotavirus GastroenteritisCroatia
-
Merck Sharp & Dohme LLCCompleted
-
MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd.ParexelCompletedRotavirus GastroenteritisBangladesh
-
PATHCenters for Disease Control and Prevention; Noguchi Memorial Institute for... and other collaboratorsCompletedRotavirus GastroenteritisGhana
-
GlaxoSmithKlineCompletedRotavirus GastroenteritisGreece
-
Shantha Biotechnics LimitedCompletedRotavirus GastroenteritisIndia
Clinical Trials on Rotateq vaccine
-
Merck Sharp & Dohme LLCCompletedVomiting | Diarrhea | Fever
-
Merck Sharp & Dohme LLCCompletedGastroenteritis | Rotavirus
-
Children's Hospital of MichiganMerck Sharp & Dohme LLC; Boston Children's Hospital; William Beaumont HospitalsCompletedShort Bowel SyndromeUnited States
-
Dennis ClementsMerck Sharp & Dohme LLCCompletedGastroenteritis | DiarrheaUnited States
-
Merck Sharp & Dohme LLCCompletedRotavirus Gastroenteritis
-
Sanofi Pasteur, a Sanofi CompanyActive, not recruitingPneumococcal ImmunizationAustralia, Puerto Rico, Honduras, South Korea, United States, Thailand
-
Children's Hospital Medical Center, CincinnatiCenters for Disease Control and PreventionCompletedIntussusception | Rotavirus InfectionsUnited States
-
Merck Sharp & Dohme LLCCompletedGastroenteritis | Rotavirus